1. Scrip
  2. >>Business

Chinook Will Soon Have $275m To Advance Kidney Disease Strategy

Company’s Reverse Merger, New Financing Will Fund Four Clinical Trials

 
• By Mandy Jackson

Chinook launched less than two years ago to develop precision medicines for chronic kidney diseases and will have three drugs in the clinic in 2021, including a Phase III candidate for IgA nephropathy.

Image of human hands holding plant shaped like dollar
Chinook raised $65m last year but will have $275m later this year • Source: Shutterstock

Chinook Therapeutics, Inc. emerged a year ago with preclinical precision medicines for chronic kidney diseases and $65m in series A venture capital. Now, the company is about to close a merger with Aduro Biotech, Inc. and announced a $106m private placement financing, which will give Chinook at least $275m in total capital to advance its pipeline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.